Directs the commissioner of health to conduct a sickle cell disparity study

◆ The sponsor's argument

Why Kevin S. Parker says this is needed

Sickle cell disease (SCD) is a genetic disorder with s gndficant public health implications. Many people, including healthcare professionals, may lack awareness about SCD, leading to delayed diagnosis and inade- quate and inequitable care. The chronic pain episodes (crises) that sickle cell patients often experience are often inadequately addressed or stigmatized, leading to undertreatment. Sickle cell disease histor- ically receives less research funding compared to other genetic disor- ders, and possibly other chronic illnesses, limiting the development of new treatments and therapies. A statewide sickle cell disparity study can identify and address poten- tial disparities in healthcare access, ensuring that individuals with SCD receive equitable treatment compared to those with other chronic illnesses. This promotes health equity and fairness in healthcare provision. Sickle cell disease has unique medical requirements, includ- ing pain management, regular monitoring, and specialized care. Under- standing if there are disparities can lead to tailored interventions to meet the specific needs of this patient population. This study may reveal if individuals with SCD are being underdiagnosed or undertreated compared to those with other chronic illnesses, shedding light on gaps in the healthcare system. Sickle cell disease often requires ongoing medical care and can impose a significant financial burden on individuals and their families. Assessing affordability can highlight economic challenges and inform policies to alleviate financial strain. Disparities in accessibility and affordability may contribute to variations in health outcomes. Understanding these disparities can lead to interventions aimed at improving health outcomes for individuals with SCD. The findings of the study can inform the development of legislation and policies that address disparities and ensure that individuals with SOD have equal access to affordable and effective healthcare. The study can serve as a basis for community engagement and advocacy efforts. It empowers affected communities to raise awareness about the unique challenges they face and advocate for necessary changes in healthcare policies and practices. Understanding treatment accessibility and affordability disparities can drive research initiatives and inno- vations to improve care delivery models, reduce costs, and enhance over- all healthcare quality for individuals with SCD. It is ethically imperative to ensure that all individuals, regardless of their health condition, have equal access to healthcare. Conducting a disparity study aligns with the principles of justice and fairness in healthcare provision. This study promotes health equity, addresses unique healthcare needs, identifies potential gaps in diagnosis and treatment, alleviates financial burdens, improves health outcomes, informs legal and policy decisions, engages communities, drives research and innovation, and upholds ethical principles in healthcare.

This is the sponsor's own case for the bill, quoted from their memorandum. It is not Agora's description of what the bill does.